Zdrowie i gospodarka · 21/12/2022

FDA Clears ZYBAN Tablets for Sale, Ends Withdrawal Process

The US Food and Drug Administration (FDA) has officially determined that ZYBAN (Bupropion Hydrochloride) Tablets, Extended Release, 150 Milligrams, were not withdrawn from sale due to safety or effectiveness concerns, allowing the agency to continue approving abbreviated new drug applications (ANDAs) for the product.